Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qibai Pingfei Granules
- Development stage
- Phase 2
- Lead developer
- Lianyungang Kanion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Qibai Pingfei Granules is a Traditional Chinese Medicine (TCM) compound developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic obstructive pulmonary disease (COPD). Approved by the China National Medical Products Administration (NMPA) in December 2021 as a Class 1.1 innovative Chinese medicine, it is specifically indicated for patients in the stable phase of COPD who exhibit the TCM syndrome of Qi deficiency, phlegm obstruction, and blood stasis. The formulation is derived from clinical experience and aims to tonify Qi, strengthen the spleen, and clear phlegm. Pharmacological studies suggest that it functions by inhibiting inflammatory signaling pathways, reducing airway remodeling, and enhancing antioxidant defenses. Clinical trials have demonstrated its efficacy in improving exercise tolerance, reducing the frequency of acute exacerbations, and alleviating respiratory symptoms such as cough and shortness of breath.
- Brand names
- Qibai Pingfei Granules
- Other names
- Qibai Pingfei Keli芪白平肺颗粒
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)HMOX1 (Heme oxygenase 1)IL-6 (Interleukin 6)IL8 (C-X-C Motif Chemokine Ligand 8)MMP9 (Matrix metalloproteinase-9)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)TGFB1 (Transforming growth factor Beta-1 proprotein)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Qibai Pingfei Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qibai Pingfei Granules.